The increasing incidence of invasive fungal infections, epidemiological changes in these infections, and safety or interactions issues that might limit the use of traditional antifungal therapies explain the need for new antifungal agents. Anidulafungin is a new echinocandin with excellent activity on most Candida as well as on Aspergillus species. Its pharmacokinetic properties allow its administration without dosage adjustments in patients with hepatic and renal impairment and account for the absence of drug interactions. Anidulafungin has showed its efficacy and good tolerability in systemic candidiasis of non-neutropenic adults, including candidemia especially in fragile patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medmal.2009.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
elimination of antimicrobials during ADVanced Organ Support hemodialysis.
Front Pharmacol
December 2024
ADVITOS GmbH, Munich, Germany.
Background: Acute kidney injury (AKI) requiring continuous renal replacement therapy is common in critically ill patients. The ADVanced Organ Support (ADVOS) system is a novel hemodialysis machine that uses albumin enriched dialysate which allows the removal of protein-bound toxins and drugs. To date, data on antimicrobial removal under ADVOS has not yet been reported.
View Article and Find Full Text PDFEchinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations.
Clin Pharmacokinet
January 2025
Pharmacy Service, Division of Medicines, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
In recent years, many population pharmacokinetic (popPK) models have been developed for echinocandins to better understand the pharmacokinetics (PK) of these antifungals. This comprehensive review aimed to summarize popPK models of echinocandins (micafungin, caspofungin, anidulafungin, and rezafungin), by focusing on dosage optimization to maximize the probability of attaining the PK/PD target proposed in special populations. A search in PubMed, Embase, Web of Science, and Scopus, supplemented by the bibliography of relevant articles, was conducted from inception to March 2024, including both observational and prospective trials.
View Article and Find Full Text PDFfungaemia outbreak in a tertiary care academic hospital and emergence of a pan-echinocandin resistant isolate, Greece, 2021 to 2023.
Euro Surveill
November 2024
Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Article Synopsis
- - After COVID-19 began, there was a significant increase in invasive fungal infections globally, but the specific situation in Greece regarding fungaemias remains unclear.
- - An ongoing outbreak in a Greek hospital has led to 89 episodes of bloodstream infections over nearly three years, with these episodes occurring in waves linked to previous colonization peaks.
- - Most fungal isolates were found to be resistant to fluconazole but sensitive to other antifungals, highlighting the importance of infection control and careful use of antifungal treatments to prevent resistance.
Multiparametric LC-MS/MS method for simultaneous determination of eleven antifungal drugs and metabolites in human plasma.
J Pharm Biomed Anal
January 2025
Department of Pharmacology, Montpellier University Hospital, Avenue du Doyen Gaston Giraud, Montpellier 34090, France; Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), INSERM, University Montpellier, Montpellier 34090, France. Electronic address:
Article Synopsis
- A new liquid chromatography-tandem mass spectrometry method has been created to measure 11 antifungal drugs and their metabolites in human plasma, essential for monitoring treatment in immunocompromised patients with fungal infections.
- * This method not only optimizes settings and preparation techniques for accurate detection but also follows strict FDA and EMA guidelines to ensure reliability and performance.
- * With a quick processing time of 5 minutes per sample and minimal plasma requirement, this method supports better antifungal therapy management in critical care settings.
In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Clades in a Neutropenic Mouse Bloodstream Infection Model.
J Fungi (Basel)
August 2024
Medical Microbiology, Clinical Center, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Article Synopsis
- Rezafungin is a newly approved drug for treating candidaemia and invasive candidiasis, marking a decade-long gap in new treatments, but research on its efficacy is limited.
- The study involved testing rezafungin and other echinocandins on various fungal isolates in infected mice, focusing on their effects on survival and fungal burdens in different organs.
- Results showed that rezafungin significantly reduced fungal loads in the kidney and heart, performed comparably or better than other echinocandins, but all treatments failed to effectively target fungal growth in the brain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!